Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (91-100 of 348) with videos related to

Pageof 35
Sort By:
British Journal of Cancer|October 18, 2018
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancerViswanath Gunda, Benjamin Gigliotti, Dorothy Ndishabandi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2026
Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancerErnesto Rojas-Jimenez, Triet M Bui, Pengze Yan, et al.
European Journal of Immunology|September 30, 2003
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responsesSpencer C Liang, Yvette E Latchman, Janet E Buhlmann, et al.
The Journal of Experimental Medicine|December 17, 2009
PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsLoise M Francisco, Victor H Salinas, Keturah E Brown, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2007
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infectionScott N Mueller, Mehrdad Matloubian, Daniel M Clemens, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2011
4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infectionVaiva Vezys, Pablo Penaloza-MacMaster, Daniel L Barber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulationAndrew J Currie, Amy Prosser, Alison McDonnell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2009
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockadeErika D Reynoso, Kutlu G Elpek, Loise Francisco, et al.
International Immunology|September 12, 2013
DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1Gayatri Mukherjee, Ari Geliebter, Jeffrey Babad, et al.
Blood|October 22, 2005
Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificityNaoto Hirano, Marcus O Butler, Zhinan Xia, et al.
Pageof 35

Showing results (91-100 of 348) with videos related to

Sort By:
Pageof 35
British Journal of Cancer|October 18, 2018
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancerViswanath Gunda, Benjamin Gigliotti, Dorothy Ndishabandi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 5, 2026
Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancerErnesto Rojas-Jimenez, Triet M Bui, Pengze Yan, et al.
European Journal of Immunology|September 30, 2003
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responsesSpencer C Liang, Yvette E Latchman, Janet E Buhlmann, et al.
The Journal of Experimental Medicine|December 17, 2009
PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsLoise M Francisco, Victor H Salinas, Keturah E Brown, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2007
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infectionScott N Mueller, Mehrdad Matloubian, Daniel M Clemens, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2011
4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infectionVaiva Vezys, Pablo Penaloza-MacMaster, Daniel L Barber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulationAndrew J Currie, Amy Prosser, Alison McDonnell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2009
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockadeErika D Reynoso, Kutlu G Elpek, Loise Francisco, et al.
International Immunology|September 12, 2013
DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1Gayatri Mukherjee, Ari Geliebter, Jeffrey Babad, et al.
Blood|October 22, 2005
Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificityNaoto Hirano, Marcus O Butler, Zhinan Xia, et al.
Pageof 35